Glycyrrhetinic acid as a hepatocyte targeting unit for an anticancer drug delivery system with enhanced cell type selectivity

被引：22

作者：

Singh, Hardev ^{[1
]}

Kim, Seo Jin ^{[2
]}

Kang, Dong Hoon ^{[3
]}

Kim, Hye-Ri ^{[2
]}

Sharma, Amit ^{[1
]}

Kim, Won Young ^{[1
]}

Kang, Chulhun ^{[2
]}

Kim, Jong Seung ^{[1
]}

机构：

[1] Korea Univ, Dept Chem, Seoul 02841, South Korea

[2] Kyung Hee Univ, Sch East West Med Sci, Yongin 17104, South Korea

[3] Univ Ulsan, Coll Med, Asan Med Ctr, Seoul 138736, South Korea

来源：

CHEMICAL COMMUNICATIONS | 2018年 / 54卷 / 87期

关键词：

HEPATOCELLULAR-CARCINOMA; IN-VIVO; CANCER-THERAPY; LIVER-CANCER; CHEMOTHERAPY; PRODRUG; AGENTS; THERANOSTICS; DOXORUBICIN; ACTIVATION;

D O I：

10.1039/c8cc05175e

中图分类号：

O6 [化学];

学科分类号：

0703 ;

摘要：

Herein, we report the potential of glycyrrhetinic acid (GA) as an active targeting ligand for hepatocellular carcinoma (HCC) for the development of diagnosis/therapy using small-molecule based approaches. Our preliminary results demonstrated that GA-conjugation to diagnostic/therapeutic counterparts significantly enhanced their HCC targeting ability and excellent therapeutic efficacy.

引用

页码：12353 / 12356

页数：4

共 36 条

[1] Liver cancer: Approaching a personalized care
Bruix, Jordi
Han, Kwang-Hyub
Gores, Gregory
Llovet, Josep Maria
Mazzaferro, Vincenzo
[J]. JOURNAL OF HEPATOLOGY, 2015, 62 : S144 - S156
[2] Design, synthesis, and preliminary evaluation of doxazolidine carbamates as prodrugs activated by carboxylesterases
Burkhart, David J.
Barthel, Benjamin L.
Post, Glen C.
Kalet, Brian T.
Nafie, Jordan W.
Shoemaker, Richard K.
Koch, Tad H.
[J]. JOURNAL OF MEDICINAL CHEMISTRY, 2006, 49 (24) : 7002 - 7012
[3] Glycyrrhetinic acid-decorated and reduction-sensitive micelles to enhance the bioavailability and anti-hepatocellular carcinoma efficacy of tanshinone IIA
Chen, Fengqian
Zhang, Jinming
He, Yao
Fang, Xiefan
Wang, Yitao
Chen, Meiwan
[J]. BIOMATERIALS SCIENCE, 2016, 4 (01) : 167 - 182
[4] A Glycyrrhetinic Acid-Modified Curcumin Supramolecular Hydrogel for liver tumor targeting therapy
Chen, Guoqin
Li, Jinliang
Cai, Yanbin
Zhan, Jie
Gao, Jie
Song, Mingcai
Shi, Yang
Yang, Zhimou
[J]. SCIENTIFIC REPORTS, 2017, 7
[5] Chemotherapy and target therapy for hepatocellular carcinoma: New advances and challenges
Deng, Gan-Lu
Zeng, Shan
Shen, Hong
[J]. WORLD JOURNAL OF HEPATOLOGY, 2015, 7 (05) : 787 - 798
[6] Camptothecin delivery into hepatoma cell line by galactose-appended fluorescent drug delivery system
Dongbang, Sun
Jeon, Hyun Mi
Lee, Min Hee
Shin, Weon Sup
Kwon, Joon Kook
Kang, Chulhun
Kim, Jong Seung
[J]. RSC ADVANCES, 2014, 4 (36) : 18744 - 18748
[7] FALLON R J, 1989, Advanced Drug Delivery Reviews, V4, P49, DOI 10.1016/0169-409X(89)90037-9
[8] Impact of Nanotechnology on Drug Delivery
Farokhzad, Omid C.
Langer, Robert
[J]. ACS NANO, 2009, 3 (01) : 16 - 20
[9] Transarterial chemoembolization of hepatocellular carcinoma - agents and drugs: an overview. Part 2
Giunchedi, Paolo
Maestri, Marcello
Gavini, Elisabetta
Dionigi, Paolo
Rassu, Giovanna
[J]. EXPERT OPINION ON DRUG DELIVERY, 2013, 10 (06) : 799 - 810
[10] Development of glycyrrhetinic acid-modified stealth cationic liposomes for gene delivery
He, Zhi Yao
Zheng, Xi
Wu, Xiao Hua
Song, Xiang Rong
He, Gu
Wu, Wen Fang
Yu, Shui
Mao, Sheng Jun
Wei, Yu Quan
[J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2010, 397 (1-2) : 147 - 154

← 1 2 3 4 →